The patients with non-small cell lung cancer who develop the dermatopathy due to EGFR-TKI.
Conditions
Interventions
Bicarbonate ion bath tablet (Sparkling Hot Tab) will be added to daily bathing for 4 weeks. The water temprature will be set under 42 degrees centigrade and soaking time for the buthtab will be aroun
Sponsors
National Hospital Organization Disaster Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients with dermatopathy who are using EGFR-TKI (gefitinib, erlotinib, afatinib) for more than 2 month. The extent of dermatopathy remains stable 2 weeks proir to the enrollment. Those who are expected to continue EGFR-TKI for another 4 weeks after enrollment.
Exclusion criteria
Exclusion criteria: The patients with the history of dermatologic disorder prior to the introduction of EGFR-TKI, for example, atopic dermatitis. Females with pregnacy and lactation. Those whom the attending physicians consider not suitable to the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects on the dermatophaty after 4 weeks of use. Visual analogue scale will be checked. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactMitsuhiro Kamimura
National Hospital Organization Disaster Medical Center Department of Pulmonology
Outcome results
None listed